Anti-Tau Drug Improves Cognition, Decreases Tau Tangles in Alzheimer’s Disease Models
Drugmaker begins phase 1 clinical trial to test microtubule stabilizing-drug in mild Alzheimer’s cases.
While clinical trial results are being released regarding drugs intended to decrease amyloid production – thought to contribute to decline in Alzheimer’s disease – clinical trials of drugs targeting other disease proteins, such as tau, are in their initial phases.
Penn Medicine research presented today at the 2012 Alzheimer’s Association International Conference (AAIC) shows that an anti-tau treatment called epithilone D (EpoD) was effective in preventing and intervening the progress of Alzheimer’s disease in animal models, improving neuron function and cognition, as well as decreasing tau pathology.
By targeting tau, the drug aims to stabilize microtubules, which help support and transport of essential nutrients and information between cells. When tau malfunctions, microtubules break and tau accumulates into tangles.
“This drug effectively hits a tau target by correcting tau loss of function, thereby stabilizing microtubules and offsetting the loss of tau due to its formation into neurofibrillary tangles in animal models, which suggests that this could be an important option to mediate tau function in Alzheimer’s and other tau-based neurodegenerative diseases,” said John Trojanowski, MD, PhD, professor of Pathology and Laboratory Medicine in the Perelman School of Medicine at the University of Pennsylvania. “In addition to drugs targeting amyloid, which may not work in advanced Alzheimer’s disease, our hope is that this and other anti-tau drugs can be tested in people with Alzheimer’s disease to determine whether stabilizing microtubules damaged by malfunctioning tau protein may improve clinical and pathological outcomes.”
The drug, identified through Penn’s Center for Neurodegenerative Disease Research (CNDR) Drug Discovery Program, was previously shown to prevent further neurological damage and improve cognitive performance in animal models*. The Penn research team includes senior investigator Bin Zhang, MD, and Kurt Brunden, PhD, director of Drug Discovery at CNDR.
Bristol-Myers Squibb, who developed and owns the rights to the drug, has started enrolling patients into aphase I clinical trial in people with mild Alzheimer’s disease.
Notes about this Alzheimer’s disease research article
Contact: Kim Menard - University of Pennsylvania School of Medicine
Source: University of Pennsylvania School of Medicine press release
Original Research: 19 July 2012 Alzheimer’s Association International Conference Presentation: “Microtubule Stabilizing Drugs for Abrogation and Prevention of Alzheimer’s Disease,” during symposium on “Insights into Non-Alzheimer’s Disease Dementia Also Inform Us About Alzheimer’s Disease”
* Full research article for “Epothilone D improves microtubule density, axonal integrity and cognition in a transgenic mouse model of tauopathy” by Brunden, K.R., Zhang, B., Carroll, J., Yao, Y., Poduzak, J.S., Hogan, A.M., Iba, M., James, M.J., Xie, S., Ballatore, C., Smith, A.B., III, Lee, V.M-Y., and Trojanowski, J.Q. in Journal of Neuroscience October 2010, 30(41): 13861-13866; doi: 10.1523/JNEUROSCI.3059-10.2010
By Neuroscience News
Neuroscience News posts news from various labs, universities, hospitals and news departments around the world. Related Articles
43 Responses to Anti-Tau Drug Improves Cognition, Decreases Tau Tangles in Alzheimer’s Disease Models
You must be logged in to post a comment Login
The world’s second most famous amnesiac patient | NUIM Neuro Lab: 
Jeremy Garson:
Anti-Tau Drug Improves Cognition, Decreases Tau Tangles in Alzheimer’s Disease Models http://t.co/XK8D5eMs
Anti-Tau Drug Improves Cognition, Decreases Tau Tangles in Alzheimer’s Disease Models http://t.co/GTrAlJhG via @neurosciencenew
Anti-Tau Drug Improves Cognition, Decreases Tau Tangles in Alzheimer’s Disease Models http://t.co/GFMG4iV9 via @neurosciencenew
Anti-Tau Drug Improves Cognition, Decreases Tau Tangles in Alzheimer’s Disease Models http://t.co/GFMG4iV9 via @neurosciencenew
Anti-Tau Drug Improves Cognition, Decreases Tau Tangles in Alzheimer’s Disease Models http://t.co/XK8D5eMs
Anti-Tau Drug Improves Cognition, Decreases Tau Tangles in Alzheimer’s Disease Models http://t.co/XK8D5eMs
Anti-Tau Drug Improves Cognition, Decreases Tau Tangles in Alzheimer’s Disease Models http://t.co/XK8D5eMs
Anti-Tau Drug Improves Cognition, Decreases Tau Tangles in Alzheimer’s Disease Models http://t.co/uIUEhMdK
Anti-Tau Drug Improves Cognition, Decreases Tau Tangles in #Alzheimer's Disease Models | #Neuroscience – http://t.co/557TLkGS
Anti-Tau Drug Improves Cognition, Decreases #Tau Tangles in #Alzheimer’s Disease Models http://t.co/Y1UcqLKg via @zite #neuroscience
Anti-Tau Drug Improves Cognition, Decreases Tau Tangles in Alzheimer’s Disease Models http://t.co/XK8D5eMs
Anti-#Tau Drug Improves #Cognition, Decreases Tau Tangles in Alzheimer’s Disease Models http://t.co/KGdGLlNr via @neurosciencenew
Anti-Tau Drug Improves Cognition, Decreases Tau Tangles in Alzheimer’s Disease Models http://t.co/XK8D5eMs
Anti-Tau Drug Improves Cognition, Decreases Tau Tangles in Alzheimer’s Disease Models http://t.co/XK8D5eMs
Anti-Tau Drug Improves Cognition, Decreases Tau Tangles in Alzheimer’s Disease Models http://t.co/CPDmkSLM via @neurosciencenew
Anti-Tau Drug Improves Cognition, Decreases Tau Tangles in Alzheimer’s Disease Models http://t.co/XK8D5eMs
Anti-Tau Drug Improves Cognition, Decreases Tau Tangles in Alzheimer’s Disease Models http://t.co/JeeoaH2X
Anti-Tau Drug Improves Cognition, Decreases Tau Tangles in Alzheimer’s Disease Models http://t.co/XK8D5eMs
Anti-Tau Drug Improves Cognition, Decreases Tau Tangles in Alzheimer’s Disease Models http://t.co/XK8D5eMs
Anti-Tau Drug Improves Cognition, Decreases Tau Tangles in Alzheimer’s Disease Models: Penn Medicine research pr… http://t.co/LwyYIO7l